Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Aligos Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 49 | 1 | 27 | −21 |
| SharesConverted for a 1-for-25 split | 1.89M | 9.10K | 1.69M | −190.5K (−10.1%) |
| Value | $16.6M | $79.6K | $14.7M | −$1.82M (−11.0%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (3)
Institutions that held Aligos Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 9,067 | $78.5K | 0.00% |
| AlphaMark Advisors, LLC | 100 | $1.00K | 0.00% |
| BNP Paribas Arbitrage, SA | 3 | $26 | 0.00% |
Sold out (24)
Institutions that held Aligos Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Tang Capital Management LLC | 1,650,000 | $577.5K |
| Versant Venture Management, LLC | 1,457,937 | $510.3K |
| Opaleye Management Inc. | 1,260,000 | $441.0K |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $260.1K |
| Newtyn Management, LLC | 719,287 | $251.8K |
| Alyeska Investment Group, L.P. | 284,233 | $99.5K |
| Citadel Advisors LLC | 277,363 | $97.1K |
| State Street Corp | 107,123 | $37.5K |
| Northern Trust Corp | 91,950 | $32.2K |
| LMR Partners LLP | 50,000 | $17.5K |
| XTX Topco Ltd | 35,644 | $12.5K |
| Millennium Management LLC | 29,881 | $10.5K |
| Choate Investment Advisors | 24,000 | $8.40K |
| Prudential Financial Inc | 19,600 | $6.86K |
| HarbourVest Partners LLC | 18,783 | $6.57K |
| Two Sigma Investments, LP | 18,706 | $6.55K |
| ZWJ Investment Counsel Inc | 14,500 | $5.08K |
| Jane Street Group, LLC | 13,666 | $4.78K |
| Zullo Investment Group, Inc. | 13,000 | $4.55K |
| HighTower Advisors, LLC | 10,000 | $4.00K |
| Virtu Financial LLC | 12,306 | $4.00K |
| Creative Planning | 10,050 | $3.52K |
| Royal Bank of Canada | 511 | $0 |
| Simplex Trading, LLC | 208 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held Aligos Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 227,406 | $79.6K |